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after brief exposure to supernatants from cultures of
anti-CD3-stimulated allogeneic lymphocytes
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Summary The present study investigated the ability of supernatants collected from cultures of healthy donor-derived peripheral blood
mononuclear cells (HD-PBMCs) stimulated with anti-CD3 monoclonal antibody (MAb) (allogeneic CD3 supernatants; ACD3S) to induce, upon
brief exposure, tumour-reactive cytotoxic lymphocytes in cancer patients' PBMCs. ACD3S enhanced natural killer (NK) and lymphokine-
activated killer (LAK) cell-mediated cytotoxicity. ACD3S contained increased levels of interleukins (IL) 1, 2, 6, 7 and 12, as well as of
granulocyte-macrophage colony-stimulating factor (GM-CSF), gamma-interferon (IFN-y) and tumour necrosis factor-a (TNF-a). MAbs
against these cytokines significantly reduced the ACD3S-induced cytotoxicity. ACD3S-induced cytotoxicity was not inhibited by anti-CD4,
CD8 and MHC class MAbs, but was markedly reduced in the presence of MAb against CD18. In contrast to HD-PBMC, ACD3S derived from
cancer patients' lymphocytes exhibited lower levels of the above-mentioned cytokines and exerted reduced biological activity. In conclusion,
ACD3S are able to activate, upon short-term incubation, tumour-reactive lymphocytes from cancer patients' PBMCs that lyse a variety of
tumour targets, including autologous tumours. ACD3S contain high levels of certain cytokines that positively influence the induction of
autologous tumour-reactive lymphocytes. Such supernatants can be collected easily from healthy donors and stored until use in clinical trials
for adoptive cellular therapy of cancer. They may also be indicated in the construction of cytokine cocktails that have the ability to induce anti-
tumour cytotoxicity.
Keywords: anti-CD3 monoclonal antibody; cytotoxic lymphocyte; cytokine; tumour-infiltrating lymphocyte; peripheral blood mononuclear
cell; cancer immunotherapy
The aim of adoptive cellular therapy of cancer is the use of
immunocompetent lymphocytes with anti-tumour cytolytic
activity to eradicate tumourcells in vivo. Clinical trials ofadoptive
cellular therapy ofcancerhave focused mainly on peripheral blood
mononuclear cells (PBMCs), activated ex vivo with interleukin 2
(IL-2) (for a review see Baxevanis and Papamichail, 1994). Such
IL-2-activated killer (LAK) cells are able to lyse a variety offresh
tumour targets. LAK cells combined with exogenous IL-2 in vivo
have demonstrated anti-tumour efficacy in patients with certain
types of malignant disease (for a review see Rosenberg and
Ettinghausen, 1995). LAK activity is mediated by CD56+ natural
killer (NK) lymphocytes and a subpopulation of T-lymphocytes
and is not restricted by gene products of the major histocompati-
bility complex (MHC) (Baxevanis and Papamichail, 1994).
The high doses of IL-2 required to maintain LAK activity in
patients caused toxic reactions with undesirable clinical results.
The search for other cytokines that can induce LAK activity with
less clinical toxicity is currently being pursued; among these are
IL-7, IL-12, IL-15, granulocyte-macrophage colony-stimulating
factor (GM-CSF) and gamma-interferon (IFN-y) (Dranoff et al,
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1993; Porgador et al, 1993; Nostala et al, 1994; Gamero et al,
1995; Mehrotta et al, 1995). Other studies have focused on proto-
cols aiming at the generation of LAK activity with low-dose IL-2
combined with other cytokines. In this respect IL-1,-4,-5,-7,-12,
GM-CSF, tumour necrosis factor (TNF) and interferons have been
successfully used (Fujiwara and Grimm, 1992; Mule et al, 1987;
Owen-Schaub et al, 1988; Sone et al, 1988; Aoki et al, 1989;
Naume and Espevik, 1991; Papamichail and Baxevanis, 1992;
Gately et al, 1994; Baxevanis et al, 1995).
Another method of obtaining cytotoxic lymphocytes with the
ability to lyse tumour cells is to activate PBMCs with anti-CD3.
CD3 is a multimeric protein complex consisting of at least five
polypeptide chains. It is non-covalently associated with the T-cell
receptor on the cell surface. Cross-linking surface CD3 with anti-
CD3 MAb results in specific activation events associated with up-
regulation of the IL-2-specific receptor, cytokine synthesis and
secretion, cell proliferation and acquisition ofboth antigen-specific
and antigen-non-specific T-lymphocyte cytotoxicity (Ullman et al,
1990). Treatment of PBMCs with anti-CD3 MAb resulted in a
marked enhancement ofNK cell-mediated cytotoxicity (Ubhi et al,
1991). In mice (Yoshizawa et al, 1992), as well as in phase I/11
clinical trials in humans (Curti et al, 1993), T-lymphocytes can be
rendered more effective in tumour therapy by non-specific expan-
sion in vitro with anti-CD3 plus IL-2. Supernatants harvested from
PBMC cultures stimulated with soluble anti-CD3 have been
demonstrated to induce autologous lymphocytes ex vivo to display
durable anti-tumour cytotoxic responses in clinical trials (Osband
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Figure 1 ACD3S enhance cytotoxicity of HD-derived PBMCs against NK-sensitive (K562) or LAK-sensitive (Daudi) tumourtargets. PBMCs (n = 12) were
incubated for the indicated periods of time in culture medium supplemented with ACD3S (25%) or control supernatant (ACS, also 25%) and then tested as
effectors against the tumour targets. Mean values ± s.d. by an effector to target (E/T) ratio of 100, from the pooled data, are shown. Pooled ACD3S and ACS
were collected from the same HD-PBMCs
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Figure 2 ACD3S restores the deficient NK and LAK cytotoxicity in cancer patients. PBMCs were derived from patients with lung carcinoma (n = 2), breast
carcinoma (n = 2) and colorectal carcinoma (n = 3). Mean values ± s.d. from the pooled data are shown. ACD3S and ACS were the same as those in Figure 1
et al, 1990). In those protocols, lymphocytes were incubated for 5
days with supematants from anti-CD3-stimulated autologous cells
and then infused back to the patients. In the present study, we
demonstrate for the first time that it is possible to generate non-
MHC-restricted anti-tumour immunoreactive lymphocytes upon
short-term incubation (3 h) with cytokine-rich supematants
derived from allogeneic PBMC cultures stimulated with immobi-
lized anti-CD3 (ACD3S). These data open the possibility for the
construction of new protocols in cancer immunotherapy based
on the activation of selected lymphocyte subpopulations with
cocktails of certain cytokines in short-term cultures; this will
significantly reduce the cost, the risk ofcontamination, side-effects
and inconsistencies in the growth and expansion rates of lympho-
cytes - all ofwhich usually occur in long-term cultures.
MATERIALS AND METHODS
Patients
Surgically excised tumour specimens were obtained from patients
with metastatic melanoma (n = 10), primary renal cell (n = 3),
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Table 1 Enhancement of NK and LAK cytotoxicity in normal donors and patients with cancer after preincubation (3 h) with ACD3S
5'Cr-specific release (%)
Effector ACSa ACD3Sa
PBMCs
K562 Daudi K562 Daudi
HD (n = 28) 33± 10 13 ± 6 46± 12 (39)b 20± 11 (54)
Lung carcinoma (n = 17) 15± 7c 7± 5 27 ±9 (80) 19± 10 (171)
Breast carcinoma (n= 22) 19 ± 10 9± 6 32± 9 (68) 16±7 (78)
Ovarian carcinoma (n= 15) 23 ± 9 5± 3 39 ± 10 (69) 12 ± 3 (140)
Colorectal carcinoma (n = 19) 17 ±7 7± 2 30± 11 (76) 20± 9 (185)
Head and neck carcinoma (n= 17) 20 ± 9 9± 5 29 ±7 (45) 17 ±5 (89)
a Pooled ACD3S or ACS (control supernatants) from HD-derived PBMCs (n=5) were used. bPercentage of enhancement. cMean values ± s.d.
from the pooled data. E/T ratio = 100.
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Figure 3 Ability of ACD3S produced by mononuclear cells isolated from blood (PBMCs), solid tumour specimens (TILs) and malignant effusions (EAMNCs) to
enhance LAK cytotoxicity. ACD3S were collected from HD-derived PBMCs (n = 7), from cancer patient-derived PBMCs (lung carcinoma,n = 3; ovarian
carcinoma, n = 3; colorectal carcinoma, n = 3), from TILs (melanoma, n = 3; breast carcinoma, n = 2; head and neck carcinoma, n = 2) and from EAMNCs (lung
carcinoma, n = 3). ACS were collected from the same HD-derived PBMCs as ACD3S. Effector PBMCs from healthy donors (n = 7) and cancer patients (lung
carcinoma, n = 3; breast carcinoma, n = 3; melanoma, n = 5) were incubated in parallel cultures with each of the various ACD3S or ACS and then tested
against Daudi cell targets. Mean values ± s.d. from the pooled data are given (E/T ratio = 100)
head and neck (n = 7), breast (n = 14), and lung (n = 6) adeno-
carcinomas. Peritoneal effusions were collected frompatients with
ovarian adenocarcinoma (n = 9) or seroys ovarian carcinoma (n =
3). Pleural effusions were collected from patients with primary
lung adenocarcinoma (n = 19) and metastatic breast cancer (n = 6).
Peripheral blood was collected from patients with adenocarci-
nomas of the lung (n = 34), breast (n = 27), ovary (n = 24),
colorectal region (n = 29) and head and neck (n = 17) and
with metastatic melanoma (n = 12). Autologous tumour-specific
cytotoxicity was tested in adenocarcinomas of the lung (n = 14),
breast (n = 11), ovary (n = 10) and head and neck (n = 5). The
patients included 120 men and 90 women with an average age of
57 years ranging from 39 to 79 years. Clinical staging was II in
10.4% (n = 22), III in 52% (n = 109) and IV in 37.6% (n = 79) of
the cases. None of these patients had received preoperative anti-
tumour therapy. All patients were apprised of the study, and
consents were obtained consistent with the policies ofthe St Savas
Cancer Hospital. Peripheral blood was also collected from 95 age-
and sex-matched healthy donors.
Preparation of cells
PBMCs were isolated from 20 ml ofheparinized venous peripheral
blood viathe standardFicoll-Hypaque (Pharmacia Fine Chemicals,
Piscataway, NJ, USA) gradient density centrifugation technique.
Tumour-Infiltrating lymphocytes (TILs) were isolated from
surgically excised tumour specimens and purified from autologous
tumour cells, as reported previously (Baxevanis et al, 1994a).
Briefly, single-cell suspensions of TILs and tumour cells were
prepared mechanically and/or enzymatically using scalpels,
needles and/or collagenase type IV (Sigma, St Louis, MO, USA).
Separation oftumour cells from mononuclear cells was performed
British Journal ofCancer (1997) 76(8), 1072-1080 0 CancerResearchCampaign 1997Induction ofanti-tumour lymphocytes in cancerpatients 1075
by centrifugation on 75-100% discontinuous Ficoll-Hypaque
(Pharmacia) density gradients. Tumour cells were found on top of
the 75% Ficoll-Hypaque. TILs were found at the interface of 75%
and 100% Ficoll-Hypaque. EAMNC were isolated from specimens
ofpleural or peritoneal effusions (Baxevanis et al, 1994b) and were
separated from autologous tumour cells as described for TILs.
Cell lines
Continuously growing cell lines were used as targets for assessing
NK and LAK cytotoxicity. K562 (NK-sensitive) is a chronic
myelogenous leukaemia cell line. Daudi (LAK-sensitive) is a
Burkitt lymphoma cell line. Both cell lines were grown in culture
medium RPMI- 1640 (Gibco, Grand Island, NY, USA) supple-
mented with 10% fetal calf serum (Gibco), 2 mM i,-glutamine
(Sigma) and 100 .tg ml gentamycin (complete medium).
Preparation of ACD3S
PBMCs, TILs or EAMNCs (2 x 106 cells ml) were activated in
25-cm2 flasks (Costar, Cambridge, MA, USA), precoated with
anti-CD3 MAb, in 5 ml of complete medium. Immobilization of
anti-CD3 MAb was performed by coating the flasks with 5 .tg mlr
MAb (anti-CD3-c; Pharmingen, San Diego, CA, USA) as previ-
ously described (Armitage et al, 1990). After a 3- to 4-day incuba-
tion at 37°C with 5% carbon dioxide and 95% air, cultures were
harvested and centrifuged. Supernatants from these cultures
(ACD3S) as well as allogeneic control supernatants (ACS), which
were collected from the same cultures set up in the absence ofanti-
CD3 MAb, were filter sterilized, aliquoted and stored at -80°C
until use.
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Cytotoxicity assays
This was essentially performed as described (Baxevanis et al,
1993b). Briefly, effector PBMC (2 x 106 cells ml I) were preincu-
bated in 5 ml of complete medium supplemented with 25%
ACD3S (or with recombinant cytokines as shown in Figure 6) in
25-ml flasks (Costar) for 3 h in carbon dioxide incubators. In
blocking experiments, cytokine-specific MAbs were added to
cultures, each at 10 tg ml final concentration for the entire pre-
incubation period. Cells were then extensively washed, resus-
pended in fresh complete medium and placed in 100- tl aliquots
into wells of 96-well V-bottom plates (Costar). Tumour targets
were labelled with sodium [51Cr]chromate (Amersham UK) and
added to the effectors. The usual effector to target (E/T) ratio was
100, unless otherwise indicated. Incubation was performed for 18
h. Anti-human GM-CSF, IFN-y, TNF-ux, IL-2, IL-I1, IL-12, IL-4
MAbs were obtained from Endogen (Boston, MA, USA). Anti-
human IL-5 and IL-6 MAbs were obtained from R & D systems
Europe (Abingdon, UK) and anti-human IL-7 MAb was obtained
from Chemicon International (Temecula, CA, USA). Anti-CD4,
anti-CD8, anti-MHC class I and anti-CD18 MAbs (Chemicon),
each at a final concentration of 10 pg ml ', were added to the effec-
tors for 10 min before the addition of 5'Cr-labelled cells. All recom-
binant cytokines were obtained from R & D systems, Europe.
Quantitation of cytokines in the ACD3S
This was performed by using enzyme-linked immunosorbent assay
(ELISA) kits according to the manufacturer's instructions. ELISA
kits specific for IL-113, IL-2, IL-4, IL-6 and IL-7 were obtained
from R & D systems, Europe. IL-5, IL-10, IL-12, TNF-ou, IFN-y
and GM-CSF were quantitated with ELISA kits from Endogen.
0 ACS, autologous tumour cells
U ACD3S, autologous tumour cells
T~~~~~T
TT
I I
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Figure 4 ACD3S enhances PBMC-mediated cytotoxicity against autologous tumour cells. Autologous tumour targets were isolated from pleural malignant
effusions (lung carcinoma, n = 6; breast carcinoma, n = 1) and from excised tumour specimens (breast carcinoma, n = 6; head and neck carcinoma, n = 5).
ACD3S and ACS were collected from HD-derived PBMCs (n = 9). Mean values + s.d. from the pooled data are given (E/T ratio = 100)
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Table 2 Quantitation of cytokine levels in ACD3S from various sources
ACS ACD3S
Cytokines PBMC-HD (n = 26) PBMC-HD (n = 26) PBMC-Caa (n = 29) TILa (n = 22) EAMNCa (n = 17)
IL-1,B 55 ± 9 1936± 397b 1010 ± 276c 130± 29d 110 ± 15d
IL-2 75 ± 23 5256 ± 1082b 3805 ± 956c 292 ± 29d 237 ± 35d
IL-4 79±26 997±125b 576±139c 159±17d 162±19d
IL-5 45 ±7 879 ± 76b 327± 59c 219± 122d 202± 75d
IL-6 35 ± 10 1720 ± 537b 790± 230c 65± 32d 90± 37d
IL-7 57 ±23 1072 ± 356b 570± 130c 70± 13d 92± 29d
IL-10 45 ± 17 50 ± 13 63±25 270 ±39 295 ±35
IL-12 65 + 19 2176± 672b 1180 ± 369c 125± 29d 179± 22d
GM-CSF 39 ± 16 3577 ± 768b 2590 ± 709c 150 ± 20d 176 ± 25d
IFN-y 55 ± 20 996± 190b 699± 162c 167± 23d 196± 17d
TNF-a 35 ± 19 1897 ± 152b 1050± 250c 63± 17d 90± 23d
aPBMCs were collected from patients with lung carcinoma (n = 9), ovaran carcinoma (n = 6), melanoma (n = 7) and colorectal carcinoma (n = 7). TiLs were
collected from patients with lung carcinoma (n = 6), melanoma (n = 7), breast carcinoma (n = 6) and renal cell carcinoma (n = 3). EAMNCs were collected from
patients with lung carcinoma (n = 7), ovarian carcinoma (n = 7) and breast carcinoma (n = 3). Stimulation with immobilized anti-CD3 was performed as
described in Materials and methods. Quantitation of cytokine levels was performed separately for each sample. Mean values (pg ml-') ± s.d. from the pooled
data are given. bvs c, P< 0.05;cvs d, P< 0.005.
RESULTS
PBMC collected from HD were incubated in complete medium
supplemented with 25% ACD3S for the time periods indicated in
Figure 1, washed three times to remove excess ACD3S and then
tested as effectors against K562 (NK-sensitive) and Daudi (LAK-
sensitive) tumour targets. The shortest period of incubation that
produced a significant enhancement of cytotoxicity over control
cultures was 3 h (P < 0.05). No significant additional increase of
enhancement after 24 h of incubation was noticed (Figure 1).
ACD3S contained no detectable amounts ofanti-CD3 MAb as tested
by a murine IgG-specific ELISA kit (Pharmingen; data not shown).
We and others have demonstrated that patients with advanced
cancer exhibit reduced cytotoxic responses (Balch et al, 1983;
Monson et al, 1987; Baxevanis et al, 1993b). It was therefore of
interest to test the ability of ACD3S to restore such deficient
responses in an effort to provide a basis for future use ofACD3S in
cancer immunotherapy. As shown in Figure 2, ACD3S derived
from HD-PBMCs was capable offully restoring the NK and LAK
cytotoxicity in a restricted number (n = 7) of cancer patients at all
E/T ratios. These findings were also extended to a higher number
ofpatients. As presented in Table 1, ACD3S greatly increased the
killing ofboth K562 and Daudi tumour targets by effector PBMCs
from 90 patients with different types of cancer. The percentages of
enhancement ranged between 39% and 80% for NK cytotoxicity
and between 54% and 185% for LAK cytotoxicity. Preincubation
of PBMC in plain medium for 3 h resulted in equal levels of cyto-
toxicity (not shown) to those obtained upon preincubation with
control supernatants (ACS) collected from the same PBMC
cultures in the absence ofanti-CD3 (Table 1).
It has been reported that mononuclearcells freshly isolated from
the tumour environment exhibit decreased immunological parame-
ters in terms of proliferation and cytotoxicity (Miescher et al,
1988; Alexander et al, 1993). Thus, we examined whether this
unresponsiveness in TILs and EAMNCs would also result in
production of inactive supernatants upon stimulation with immo-
bilized anti-CD3 MAbs. Indeed, ACD3S derived from TILs
(melanoma, breast carcinoma, head and neck carcinoma, n = 7)
and EAMNCs (lung carcinoma, ovarian carcinoma, n = 6) did not
significantly enhance the killing of Daudi tumour targets upon
preincubation for 3 h with either HD- or patient-derived PBMCs
(Figure 3). Even prolonged preincubation (24 h) or higher doses
(complete medium supplemented with 50% of such supernatants)
did not improve the cytotoxicity levels (data not shown). In
contrast, stimulation ofpatients' PBMCs (n = 9) with immobilized
anti-CD3 MAb resulted in ACD3S that significantly enhanced the
killing of Daudi targets by both HD- and patient-derived PBMCs
(P < 0.01; Figure 3). However, this enhancement was significantly
lower than that induced by ACD3S derived from HD-PBMCs
(P < 0.05; Figure 3).
As cellular adoptive immunotherapy of cancer is based on the
eradication ofautologous tumour cells in vivoby ex vivo-activated
cytotoxic lymphocytes, we were interested in determining whether
ACD3S were capable of enhancing in vitro the killing of tumour
cells by autologous PBMCs. The data in Figure 4 clearly show that
ACD3S from HD-derived PBMCs induced a two- to three-fold
increase ofautologous tumour-cell killing in all 18 cases tested. In
these experiments (and those ofFigures 5-7), tumour cells isolated
from surgically excised tumour specimens or malignant (pleural,
peritoneal) effusions were kept frozen in liquid nitrogen until
blood was withdrawn from the same patients for isolation of
autologous PBMCs.
There are numerous reports demonstrating the involvement of
various cytokines alone or in synergy with IL-2 in cytotoxic
responses against tumour cells (Owen-Schaub et al, 1988; Aoki et
al, 1989; Naume and Espevik, 1991; Fujiwara and Grimm, 1992;
Baxevanis et al, 1995). On the other hand, the data presented
herein show that there are significant differences between ACD3S
from HD-derived PBMCs and cancer patient-derived PBMCs,
TILs or EAMNCs, with respect to their capacity to induce
enhanced cytotoxicity (Figure 3). Thus, it was ofinterest to corre-
late the potency of such supernatants to enhance killing oftumour
cells with the levels of certain cytokines that are involved in this
type of response. Cytokine analyses were performed in a large
number ofsamples for every group to allow statistical comparison
(Table 2). High levels of various cytokines could be detected in
all ACD3S from healthy donors. Increased levels of the
same cytokines were also detected in the ACD3S from cancer
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Figure 5 Cytokine-specific MAbs reduce the ACD3S-induced enhancement
of cytotoxic responses. MAbs were present throughout the preincubation
period of PBMCs with ACD3S. Thereafter, PBMCs were washed three times
to remove residual of supernatant and MAb and used as effectors in the
cytotoxic assays. ACD3S were the same as those of Table 2. Autologous
tumour cells were isolated from malignant peritoneal (ovarian carcinoma,
n = 5) and pleural (breast carcinoma, n= 2; lung carcinoma, n= 3)
effusions. Pooled data + sd are shown. PBMCs from the same patients
were used as effectors. Inhibition was statistically significant (P < 0.05),
except with anti-IL-4 and anti-IL-5 MAbs
patient-derived PBMCs which, however, were significantly lower
than those from healthy donors (Table 2). In agreement with the
data of Figure 3, there was a tremendous decrease in the amounts
of these cytokines in ACD3S from TILs and EAMNCs.
Interestingly, fivefold higher levels of IL- 10 could be measured in
ACD3S from TILs and EAMNCs, which may be associated with
their inability to stimulate anti-tumour cytotoxicity in PBMCs.
To directly correlate the presence of the above cytokines with
the ability ofACD3S to enhance the PBMC-mediated cytotoxicity,
we performed blocking cxperiments by adding cytokine-specific
MAbs along with the ACD3S for the duration of'the 3-h preincu-
bation. MAb against IL-1D, IL-2, IL-6, IL-7, IL-12, GM-CSF,
IFN-y and TNF- significantly reduced the ACD3S-induced
enhanced cytotoxicity against Daudi (reduction range 35-50%)
'9
3dd 4
Figure 6 Superior immunopotentiating effect of ACD3S to simple
incubation of PBMCs with each recombinant cytokine alone. Patients'
PBMCs (lung carcinoma, n = 2; breast carcinoma, n = 2; ovarian carcinoma,
n = 2) were incubated for 3 h with ACD3S or each of the recombinant
cytokines and then tested for cytotoxicity against Daudi or autologous tumour
cells. ACD3S was collected from HD-derived PBMCs (n = 5). First, second,
third and fourth doses for each of the recombinant cytokines used were,
respectively: 1000, 100, 10 and 1 IU ml-' for IL-2; 100, 10, 1 and 0.1 ng ml-'
for IL-1, IL-6 and IL-12; 200, 20, 2 and 0.2 ng ml-' for GM-CSF, IFN-y and
TNF-o (final concentrations)
and autologous tumour targets (reduction range 36-56%) (Figure
5). In the same experiments MAbs against IL-4 and IL-5 remained
without any significant effect, suggesting that both cytokines did
not contribute to the observed enhancement of cytotoxicity. Even
at higher doses (20 or 40 tg ml '), anti-IL-4 and anti-IL-5 MAbs
did not effectively inhibit the ACD3S-mediated augmented effect
(data not shown). These results confirm that a synergy of certain
cytokines, present in excess within the ACD3S, is responsible for
the observed enhancement of the anti-tumour cytotoxic responses.
The superior immunostimulatory effect of the ACD3S to simple
incubation with each of these cytokines alone was documented in
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not MHC-restricted, as none of the anti-CD4, anti-CD8 or anti-
MHC class I MAbs showed an inhibitory effect. In contrast, anti-
CD 18 MAb markedly inhibited (average inhibition 51%) lysis of
Daudi and autologous tumour cells (Figure 7). These data suggest
that lysis of tumour targets by ACD3S-activated PBMCs is medi-
ated by non-MHC-restricted cells whereby the CD18 adhesion
molecule plays a critical role.
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Figure 7 CD1 8-dependent lysis of tumour targets by ACD3S-activated
PBMCs. MAbs were added to the effectors 10 min before the addition of the
5'Cr-labelled tumour targets. Patients and ACD3S were the same as in Figure
5. Inhibition with anti-CD18 MAb was statistically significant (P < 0.01)
the next series of experiments. As shown in Figure 6, none of the
cytokines alone could enhance killing of Daudi or autologous
tumour targets by patients' PBMCs. Only IL-2 at a high dose
(1000 IU ml-') could promote cytotoxicity to levels that, however,
were significanty lower than those achieved with ACD3S (20% vs
33% killing against Daudi and 17% vs 32% killing against
autologous tumour targets; in both cases, P < 0.05).
Cytolytic activity depends on the binding of the effector
lymphocytes to the tumour target cells. In this process, accessory,
MHC and adhesion molecules have been reported to be involved
(Baxevanis and Papamichail, 1994; Gamero et al, 1995). To test
which molecules are involved in the recognition of tumour targets
by the ACD3S-activated effectors, MAbs against CD4, CD8,
MHC class I and CD18 molecules were added to the lytic assay to
examine their ability to inhibit cytotoxic function. Experiments
from six patients demonstrate that the ACD3S-induced cytotoxic
responses against both Daudi and autologous tumour targets were
DISCUSSION
The data presented herein describe the ability of supernatants from
cultures of healthy donor-derived PBMCs with immobilized anti-
CD3 MAb (ACD3S) to induce, upon 3-h preincubation, tumour-
reactive cytotoxic lymphocytes among PBMCs from cancer
patients with advanced disease. Cytotoxicity was directed against
both allogeneic tumours or tumour cell lines and autologous
tumour cells. A number of cytokines, such as IL-1(, IL-2, IL-6,
IL-7, IL-12, GM-CSF, IFN-y and TNF-oc present at high titres
within the ACD3S, were responsible for the induction of cytotoxi-
city. This was shown by two different means: (1) cytokine-specific
antibodies added to the effector PBMCs in the presence of ACD3S
diminished, to a great extent, the enhancement ofcytotoxicity; and
(2) ACD3S derived from TILs and EAMNCs contained drastically
lower (six- to 30-fold) quantities ofthe above mentioned cytokines
and accordingly produced little if any effect. The fact that IL-4 and
IL-5, although detected at increased levels within the ACD3S, did
not significantly intluence the observed enhancement of cytotoxi-
city may simply be as a result of the culture system used. We have
shown that 3 h of incubation yields a prominent enhancement of
cytotoxicity that does not significantly differ from that obtained
upon 24-h preincubation (Figure 1). Therefore, we believe that
incubation of PBMC with ACD3S over 24 h, in an effort to detect
any IL-4- and IL-5-mediated enhancing effects, would not addi-
tionally serve the aim ofthe present study.
ACD3S from TILs and EAMNCs contained increased levels of
IL-10. This cytokine can suppress the secretion of other
cytokines, such as IFN-y, IL-1(3, IL-6 and TNF-oc (Fiorentino et
al, 1991; DeWaal-Malefyt et al, 1993: Taga et al, 1993) and there-
fore may be responsible for the low titre of cytokines present
within the TIL- and EAMNC-derived ACD3S. Neutralizing the
biological activity of IL-10 by anti-IL-10 MAb during ACD3S
production may clarify its role in this sytem. On the other hand, it
is known that freshly isolated TILs and EAMNCs are functionally
impaired, with abnormal in vitro proliferation to polyclonal acti-
vators (Miescher et al, 1987, 1988; Alexander et al, 1993). This
lack of responsiveness could also account for the low cytokine
levels within such supernatants. In contrast to TILs and
EAMNCs, PBMCs from cancer patients were able to produce
biologically active ACD3S with elevated titres of the relevant
cytokines. However, the enhancing effect induced by such super-
natants was significantly weaker than that of HD-PBMCs. This
was not because of the levels of IL-10 as these were almost
equally low in ACD3S from both groups, but rather to the levels
of the crucial cytokines (i.e. IL-1 , -2, -6, -7, -12 and GM-CSF,
IFN-y and TNF-oc), which were significantly lower (1.4- to 2.2-
fold) in ACD3S from patients' PBMCs. In accordance with this,
preliminary data from our laboratory suggest that such super-
natants can be as effective as those from healthy donors when
their content in culture is increased. Cellular immunity in cancer
patients with advanced disease has been reported to be impaired
in several aspects, including T-cell activation and proliferation, to
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a variety of stimuli (Monson et al, 1987; Anastasopoulos et al,
1992; Kosmidis et al, 1992; Baxevanis et al, 1993a,c; Such defi-
ciencies may contribute to the production of less active super-
natants by patients' PBMCs.
There are numerous reports demonstrating the capacity of anti-
CD3 MAb to induce cytotoxic responses in a variety of systems.
Suthanthiran et al (1984) were the first to show that pretreatment
of human alloreactive memory cells, generated in primary mixed
lymphocyte cultures, with anti-CD3 resulted in the induction of
specific secondary cytolytic activity and natural killer cell-like
activity. Murine TILs sequentially activated with solid-phase anti-
CD3 produced increased levels ofIFN-yand GM-CSF in vitro and
were capable oferadicating pulmonary metastases induced by the
MCA-105 sarcoma in vivo (Geodegebuure et al, 1994). In another
study (Katsanis et al, 1994), short-term ex vivo activation of
splenocytes with anti-CD3 plus IL-2 and infusion post-bone
marrow transplantation into mice resulted in in vivo expansion of
effector cells with potent anti-lymphoma activity. In vivo adminis-
tration of anti-CD3 MAb plus IL-2, induced intrahepatic expres-
sion of mRNA-encoding perforin, cytotoxic T-cell-specific serine
esterase and TNF-a that resulted in a significantly smaller number
of hepatic metastases and significantly longer survival time of
tumour-bearing mice (Nakajama et al, 1994). In humans, immobi-
lized anti-CD3, along with IL-2, has successfully been used for
large-scale expansion of PBMCs with non-MHC-restricted cyto-
toxicity for adoptive cellular immunotherapy after bone marrow
transplantation (Uberti et al, 1994). Immobilized anti-CD3, along
with IL-2, has been demonstrated to induce high cytotoxicity
against autologous tumour cells in cytotoxic T-cells generated
during an autologous mixed lymphocyte tumour-cell culture (Tani
et al, 1995). Anti-CD3 has also been shown to stimulate LAK cells
to lyse acute myeloid leukaemia cells (Kaneko et al, 1994) and to
induce in vitro expansion and activation of mucin-reactive T-
helper lymphocytes from patients with colorectal cancer (Kim et
al, 1995). Finally, in a recent clinical study (Goedegebuure et al,
1995), TILs activated with anti-CD3 MAb for 48 h and expanded
in low-dose IL-2 in vitro produced high levels of IL-6, GM-CSF,
TNF-a and IL-4 with improved clinical results in patients with
melanoma and renal cell carcinoma.
Our results yield additional information regarding the ability of
anti-CD3 MAb to induce cytotoxic responses. We consistently
measured high levels ofIL-I,, -2, -6, -7, -12 and GM-CSF, TNF-
a and IFN-y in the ACD3S from all 55 donor PBMCs tested (26
healthy donor and 29 carcinoma PBMC). All these cytokines have
previously been shown to be potent inducers of anti-tumour cyto-
toxicity by activating both effectors with specificity against autol-
ogous tumours and effectors that lyse a broad spectrum of
allogeneic tumours (Mule et al, 1987; Fujiwara and Grimm, 1992;
Porgador et al, 1993; Nostala et al, 1994; Baxevanis et al, 1995).
To our knowledge, this is the first report that demonstrates such a
synergy between endogenously produced cytokines in the induc-
tion oftumour-reactive lymphocytes within only 3 h ofincubation.
The term 'synergy' is applied because (1) none of the cytokine-
specific MAbs used was able to completely blockthe response and
(2) none of these cytokines alone, with the exception of IL-2 at
high doses, was able upon 3-h incubation to increase the patients'
PBMCs cytotoxic capacity. The lytic activity induced by ACD3S
in patients' PBMCs is non-MHC-restricted and at least partly
CD18 dependent. The non-MHC-restricted lysis was demon-
strated by two means: (1) by the fact that anti-CD4, anti-CD8 and
anti-MHC class I MAbs failed to inhibit lysis against autologous
tumour cells and Daudi cells; (2) ACD3S-activated effectors were
able to lyse K562 cells, which are MHC class I negative, as well as
Daudi cells and primary allogeneic tumour cells, which express
different MHC class I molecules. The initiation of the cytolytic
process requires contact ofthe tumour cells with the effector cells,
and an essential component is the interaction of ICAM-1 on the
tumour targets with CD18 on the effectors (Blauchard et al, 1990).
Our data demonstrate that this molecule also participates in the
cytotoxic process induced by ACD3S against autologous and allo-
geneic tumour cells, as well as against tumour cell lines. As the
lytic activity enhanced by ACD3S is non-MHC restricted, CD18
must be expressed on activated CD56+ cells, which mediate this
type ofcytotoxicity (Baxevanis and Papamichail, 1994).
In conclusion, we demonstrate herein that cytokine-rich super-
natants produced by anti-CD3-activated HD-PBMCs during a 3-h
incubation can induce cancer patients' lymphocytes to lyse a
variety of tumour targets, including autologous tumour cells.
These data suggest the therapeutic use of the application of such
supernatants for a short-term activation of patients' PBMCs
collected with leucapheresis. Mixtures of recombinant cytokines
(such as those detected in the ACD3S) may also be used in this
respect. We believe that this approach offers several advantages
over that introduced by Osband et al (1990), which is based on the
use of supernatants derived from activated autologous (cancer
patient derived) PBMCs. First, ACD3S are derived from PBMCs
of (allogeneic) healthy donors which, as shown herein, are supe-
rior to those collected from cancer patients in terms of inducing
cytotoxicity against tumour targets, including patients' tumours.
Second, ACD3S can be collected easily from healthy donor-
derived PBMCs, pooled at high quantities and stored until use. In
this way, sufficient material (ACD3S) will be available at any time
for immunotherapeutic trials. In addition, this approach offers a
less costly method of cancer immunotherapy using ex vivo-acti-
vated effector lymphocytes with non-MHC-restricted cytotoxicity.
This method could make cellular adoptive immunotherapy more
accessible to cancerpatients and reduce the dependency oftherapy
on the availability of a large-scale culture facility as well as the
reported side-effects that are associated with this type oftherapy.
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